Peyro Saint Paul Laure, Martin Jocelyne, Buon Marie, Gaillard Cathy, Fedrizzi Sophie, Mosquet Brigitte, Coquerel Antoine
CHU de Caen, Service de Recherche clinique, Caen, France.
Hôpital de Carentan, Carentan, France.
Therapie. 2014 Mar-Apr;69(2):157-62. doi: 10.2515/therapie/2014019. Epub 2014 Jun 12.
Hyponatremia is a rare side effect described in the product characteristics of proton pump inhibitors (PPIs). Hyponatremia in the elderly (>65 years) was assessed in patients with exposure to PPIs for at least one year compared to controls not exposed to PPIs counterparts. Included 145 patients, twenty-four patients (16.6%) had moderate hyponatremia ([120-134] mEq/L). Forty-eight patients (33.1%) were treated with PPIs. In the end, 31.3% [18.7%-46.3%] of the treated population for more than a year by PPI suffered moderate hyponatremia against only 9.3% [14.3%-16.9%] in the rest of the population, giving an odds ratio of 4.4 ([1.8-11.1], p=0.001). The relationship between hyponatremia dose was not significant (R2=0.05, p=0.74). By our study, we show that the risk of moderate hyponatremia is increased by chronic use of PPI in the elderly population. We also specify a notion of prevalence between 18.7% and 46.3%.
低钠血症是质子泵抑制剂（PPI）产品特性中描述的一种罕见副作用。在暴露于PPI至少一年的老年患者（>65岁）中评估低钠血症情况，并与未暴露于PPI的对照组进行比较。纳入145例患者，24例患者（16.6%）患有中度低钠血症（[120 - 134] mEq/L）。48例患者（33.1%）接受了PPI治疗。最终，接受PPI治疗超过一年的人群中有31.3% [18.7% - 46.3%]患有中度低钠血症，而其余人群中这一比例仅为9.3% [14.3% - 16.9%]，优势比为4.4（[1.8 - 11.1]，p = 0.001）。低钠血症与剂量之间的关系不显著（R2 = 0.05，p = 0.74）。通过我们的研究表明，老年人群长期使用PPI会增加中度低钠血症的风险。我们还明确了患病率在18.7%至46.3%之间。
